ProCE Banner Activity

LEGEND-2 Long-term Follow-up: Phase I Trial of LCAR-B38M CAR T-Cell Therapy in R/R MM

Slideset Download
Conference Coverage
Long-term follow-up of LEGEND-2 suggests LCAR-B38M CAR T-cell therapy highly active in patients with relapsed/refractory multiple myeloma.

Released: December 13, 2019

Expiration: December 11, 2020

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company